Analyst Actions: CCE, CMOS, EMBT, KEA, XL
Coca-Cola Enterprises' (CCE) fiscal 2000 earnings estimates were lowered to 50 cents from 68 cents a share at UBS Warburg Dillon Read. Its fiscal 2001 estimate was lowered to 70 cents from 90 cents.
Merrill Lynch
lowered the company's fiscal 2000 estimate to 45-50 cents a share from 68 cents and for fiscal 2001 to 65 cents from 95 cents a share. Merrill also downgraded the company's intermediate-term rating to neutral from buy.
Upgrade
Credence Systems
(CMOS)
: fiscal 2000 estimates UP to $5.05 from $4.25 at
Credit Suisse First Boston
; fiscal 2001 estimates UP to $7.10 from $6.10.
Initiations
Embarcadero Technologies
(EMBT)
: NEW buy at
Donaldson Lufkin & Jenrette
; price target of 40.
Keane
(KEA)
: NEW intermediate accumulate, long-term buy rating at Merrill Lynch.
XL Capital
(XL) - Get Report
: NEW strong buy at
UBS Warburg Dillon Read
; price target of 65.
Group Moves
SG Cowen
upgraded the following biotech stocks:
- Genzyme Molecular (GZMO) : NEW strong buy ;price target: 25.
Genzyme Transgenics (GZTC) : NEW strong buy; price target: 28.
Millennium Pharmaceuticals (MLNM) : NEW strong buy.
Lehman Brothers
upgraded the following retail stocks:
- Dollar General (DG) - Get Report: NEW outperform.
Family Dollar (FDO) : NEW outperform.
Chase H&Q
started the following HMOs with strong buy ratings:
- Oxford (OXHP) UnitedHealth (UNH) - Get ReportWellpoint (WLP) .
